Search
forLearn
5 / 801 resultslearn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn retinoic acid
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
Research
5 / 428 resultsresearch Effectiveness and Safety Profile of Cisplatin Versus Nab-Paclitaxel Concomitant Chemoradiotherapy in Postoperative Early-Stage Cancer of Cervix
Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.
research Cancer risk in patients with alopecia areata: a nationwide population‐based matched cohort study
Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.
research Cervical cancer metastasis to the scalp presenting as alopecia neoplastica
A woman with cervical cancer had rare scalp metastasis causing a unique type of hair loss.
research Alopecia prevention during chemotherapy: from the benchmark to real clinical practice. A prospective study
Scalp cooling effectively prevents hair loss during chemotherapy in most cases.
research Cancer risk by the subtype of alopecia
People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.
Community Join
5 / 1000+ resultscommunity Hair Loss Breakthrough: Keratin Microsphere Gel Initiates Hair Regrowth in Days by Directly Targeting Follicles and Boosting Gene Expression - Gilmore Health News
A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.
community Clascoterone full results in July
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
community Clascoterone (Winlevi) Update for Canada
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
community PCOS female with significant receding and thinning; doctor won’t give me anything but Spiro and Spiro sucks
Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.